Gilead Sciences [GILD] vs Pfizer [PFE] Detailed Stock Comparison
Gilead Sciences
NASDAQ
Loading...
Pfizer
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gilead Sciences wins in 10 metrics, Pfizer wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Gilead Sciences | Pfizer | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 23.78 | 17.02 | Pfizer |
| Price-to-Book Ratio | 7.35 | 1.48 | Pfizer |
| Debt-to-Equity Ratio | 130.79 | 68.84 | Pfizer |
| PEG Ratio | 15.23 | 8.02 | Pfizer |
| EV/EBITDA | 11.44 | 7.67 | Pfizer |
| Profit Margin (TTM) | 20.76% | 12.62% | Gilead Sciences |
| Operating Margin (TTM) | 38.49% | 35.17% | Gilead Sciences |
| EBITDA Margin (TTM) | 38.49% | 35.17% | Gilead Sciences |
| Return on Equity | 32.65% | 8.62% | Gilead Sciences |
| Return on Assets (TTM) | 12.14% | 4.79% | Gilead Sciences |
| Free Cash Flow (TTM) | $10.31B | $9.84B | Gilead Sciences |
| Dividend Yield | 2.84% | 5.32% | Pfizer |
| 1-Year Return | 47.43% | -22.81% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 4.90 | 2.14 | Pfizer |
| Enterprise Value | $156.94B | $178.93B | Pfizer |
| EV/Revenue Ratio | 5.46 | 2.86 | Pfizer |
| Gross Profit Margin (TTM) | 76.90% | 79.26% | Pfizer |
| Revenue per Share (TTM) | $23 | $11 | Gilead Sciences |
| Earnings per Share (Diluted) | $4.76 | $1.38 | Gilead Sciences |
| Beta (Stock Volatility) | 0.31 | 0.50 | Gilead Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Gilead Sciences vs Pfizer Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gilead Sciences | 0.79% | -2.60% | 1.30% | 9.62% | 15.04% | 23.18% |
| Pfizer | 0.86% | -5.24% | -6.19% | -1.84% | -10.34% | -11.72% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gilead Sciences | 47.43% | 85.27% | 63.20% | -1.10% | 531.94% | 961.73% |
| Pfizer | -22.81% | -52.32% | -35.61% | -29.65% | 52.43% | -5.70% |
Performance & Financial Health Analysis: Gilead Sciences vs Pfizer
| Metric | GILD | PFE |
|---|---|---|
| Market Information | ||
| Market Cap | $140.79B | $133.55B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 5,545,080 | 40,445,720 |
| 90 Day Avg. Volume | 6,876,600 | 40,198,617 |
| Last Close | $113.18 | $23.49 |
| 52 Week Range | $72.43 - $119.96 | $20.92 - $31.32 |
| % from 52W High | -5.65% | -25.00% |
| All-Time High | $123.37 (Jun 22, 2015) | $61.71 (Dec 20, 2021) |
| % from All-Time High | -8.26% | -61.93% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | -0.08% |
| Quarterly Earnings Growth | 0.00% | -0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.21% | 0.13% |
| Operating Margin (TTM) | 0.38% | 0.35% |
| Return on Equity (TTM) | 0.33% | 0.09% |
| Debt to Equity (MRQ) | 130.79 | 68.84 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.39 | $15.89 |
| Cash per Share (MRQ) | $7.00 | $3.05 |
| Operating Cash Flow (TTM) | $10.37B | $13.99B |
| Levered Free Cash Flow (TTM) | $9.99B | $15.05B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.84% | 5.32% |
| Last 12-Month Dividend | $3.12 | $1.27 |
Valuation & Enterprise Metrics Analysis: Gilead Sciences vs Pfizer
| Metric | GILD | PFE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 23.78 | 17.02 |
| Forward P/E | 15.23 | 8.02 |
| PEG Ratio | 15.23 | 8.02 |
| Price to Sales (TTM) | 4.90 | 2.14 |
| Price to Book (MRQ) | 7.35 | 1.48 |
| Market Capitalization | ||
| Market Capitalization | $140.79B | $133.55B |
| Enterprise Value | $156.94B | $178.93B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.46 | 2.86 |
| Enterprise to EBITDA | 11.44 | 7.67 |
| Risk & Other Metrics | ||
| Beta | 0.31 | 0.50 |
| Book Value per Share (MRQ) | $15.39 | $15.89 |
Financial Statements Comparison: Gilead Sciences vs Pfizer
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GILD | PFE |
|---|---|---|
| Revenue/Sales | $6.67B | $13.72B |
| Cost of Goods Sold | $1.54B | $2.85B |
| Gross Profit | $5.13B | $10.87B |
| Research & Development | $1.38B | $2.20B |
| Operating Income (EBIT) | $2.49B | $4.43B |
| EBITDA | $3.28B | $6.48B |
| Pre-Tax Income | $1.65B | $2.79B |
| Income Tax | $334.00M | $-189.00M |
| Net Income (Profit) | $1.32B | $2.97B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GILD | PFE |
|---|---|---|
| Cash & Equivalents | $7.93B | $1.43B |
| Total Current Assets | $16.90B | $45.86B |
| Total Current Liabilities | $12.34B | $36.45B |
| Long-Term Debt | $22.15B | $56.82B |
| Total Shareholders Equity | $19.08B | $90.64B |
| Retained Earnings | $10.93B | $119.59B |
| Property, Plant & Equipment | $7.96B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GILD | PFE |
|---|---|---|
| Operating Cash Flow | $1.56B | $3.91B |
| Capital Expenditures | $-104.00M | $-564.00M |
| Free Cash Flow | $1.65B | $1.77B |
| Debt Repayment | $-1.76B | $-2.43B |
| Common Stock Repurchase | $-730.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GILD | PFE |
|---|---|---|
| Shares Short | 22.54M | 99.27M |
| Short Ratio | 2.80 | 2.53 |
| Short % of Float | 0.02% | 0.02% |
| Average Daily Volume (10 Day) | 5,545,080 | 40,445,720 |
| Average Daily Volume (90 Day) | 6,876,600 | 40,198,617 |
| Shares Outstanding | 1.25B | 5.67B |
| Float Shares | 1.24B | 5.68B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.90% | 0.68% |
Dividend Analysis & Yield Comparison: Gilead Sciences vs Pfizer
| Metric | GILD | PFE |
|---|---|---|
| Last 12-Month Dividend | $3.12 | $1.27 |
| Last 12-Month Dividend Yield | 2.84% | 5.32% |
| 3-Year Avg Annual Dividend | $3.04 | $1.52 |
| 3-Year Avg Dividend Yield | 0.93% | 1.27% |
| 3-Year Total Dividends | $9.12 | $4.55 |
| Ex-Dividend Date | Jun 13, 2025 | Jan 24, 2025 |